Retraction
ACP-196, An Orally Bioavailable Covalent Selective Inhibitor of Btk, Modulates the Innate Tumor Microenvironment, Exhibits Antitumor Efficacy and Enhances Gemcitabine Activity in Pancreatic Cancer
Paper Information
Record ID:
10789
Author(s):
Journal:
Publication Date:
August 02, 2015
Retraction Date:
August 31, 2017
(8.2 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institution:
Acerta Pharma, San Carlos, CACountry:
🇺🇸 United StatesArticle Type:
Publisher:
American Association for Cancer Research
Open Access:
Yes
PubMed ID:
Not indexed in PubMed
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1158/0008-5472.CAN-17-2154Citations (6)
6
Total Citations3
Post-Retraction(50.0%)
2
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
1
Within 1 year
1
After 2+ years
809
Days since retraction (latest)
Paper citing ACP-196, An Orally Bioavailable Covalent Selective...
Unknown Authors
Unknown Journal
Published: Nov 2019
809 days after retraction
Paper citing ACP-196, An Orally Bioavailable Covalent Selective...
Unknown Authors
Unknown Journal
Published: Nov 2018
439 days after retraction
Paper citing ACP-196, An Orally Bioavailable Covalent Selective...
Unknown Authors
Unknown Journal
Published: May 2018
243 days after retraction
Paper citing ACP-196, An Orally Bioavailable Covalent Selective...
Unknown Authors
Unknown Journal
Published: Aug 2017
Same day as retraction
Emerging role of immunotherapy in urothelial carcinoma—Future directions and novel therapies
Jong‐Chul Park, Noah M. Hahn
Urologic Oncology Seminars and Original Investigations
Published: Oct 2016
7 citations
7 citations
314 days before retraction
Paper citing ACP-196, An Orally Bioavailable Covalent Selective...
Unknown Authors
Unknown Journal
Published: Mar 2016
540 days before retraction
Quick Stats
Total Citations:
6
Years Since Retraction:
8.2 years
Open Access:
Yes
Last Checked:
Never